A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.

Affinia Therapeutics, a US-based gene therapy developer based on research at Harvard University, has filed to raise up to $100m in an initial public offering on the Nasdaq Global Market that would represent an exit for chemical producer Lonza, internet and technology group Alphabet and care provider Mass General Brigham. The company had raised $170m as of a $110m series B round in May 2021 featuring Lonza and corporate venturing units GV and Mass General Brigham Ventures.

Trifacta, a US-based data…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).